Literature DB >> 18208949

Trastuzumab treatment for breast cancer during pregnancy.

Alon Shrim, Facundo Garcia-Bournissen, Cynthia Maxwell, Dan Farine, Gideon Koren.   

Abstract

QUESTION: One of my patients has been diagnosed with breast cancer and started treatment with trastuzumab. She has recently discovered that she is pregnant and wishes to continue the pregnancy. What are the consequences of trastuzumab treatment during pregnancy and can she continue her pregnancy? ANSWER: Human data regarding the safety of trastuzumab during pregnancy are scarce. Only 3 case reports could be located in the published literature. Anhydramnios was observed in a case where the exposure to trastuzumab occurred during the second trimester, which reversed after discontinuation of the drug without any apparent consequences to the baby. Evidence is insufficient to provide any recommendations, but in light of the case reports, pregnancies exposed to trastuzumab during the second trimester should be closely followed with particular attention to amniotic fluid volume.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18208949      PMCID: PMC2329906     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  5 in total

1.  Effect of adjuvant trastuzumab on pregnancy.

Authors:  Ashita M Waterston; John Graham
Journal:  J Clin Oncol       Date:  2006-01-10       Impact factor: 44.544

2.  Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy.

Authors:  Michelle A Fanale; Anne R Uyei; Richard L Theriault; Karolina Adam; Rachel A Thompson
Journal:  Clin Breast Cancer       Date:  2005-10       Impact factor: 3.225

3.  Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios.

Authors:  William J Watson
Journal:  Obstet Gynecol       Date:  2005-03       Impact factor: 7.661

4.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Requirement for neuregulin receptor erbB2 in neural and cardiac development.

Authors:  K F Lee; H Simon; H Chen; B Bates; M C Hung; C Hauser
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

  5 in total
  4 in total

Review 1.  Breast cancer diagnosis during pregnancy.

Authors:  Jennifer K Litton; Richard L Theriault; Ana M Gonzalez-Angulo
Journal:  Womens Health (Lond)       Date:  2009-05

2.  Aggressive Breast Cancer during Pregnancy with a Rare Form of Metastasis in the Maternal Placenta.

Authors:  G Vetter; F Zimmermann; E Bruder; S Schulzke; I Hösli; M Vetter
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-06       Impact factor: 2.915

Review 3.  Breast cancer before age 40 years.

Authors:  Carey K Anders; Rebecca Johnson; Jennifer Litton; Marianne Phillips; Archie Bleyer
Journal:  Semin Oncol       Date:  2009-06       Impact factor: 4.929

Review 4.  Breast cancer and pregnancy: current concepts in diagnosis and treatment.

Authors:  Jennifer K Litton; Richard L Theriault
Journal:  Oncologist       Date:  2010-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.